中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
25期
146-147
,共2页
低分子肝素%肺心病%呼吸衰竭
低分子肝素%肺心病%呼吸衰竭
저분자간소%폐심병%호흡쇠갈
Low molecular weight heparin%Pulmonary heart disease%Respiratory failure
目的：对低分子肝素治疗肺心病并呼吸衰竭的临床效果进行研究。方法选取2013年7月～2015年7月我院接受治疗的肺心病并呼吸衰竭患者97例，将患者随机分为对照组（46例）和治疗组（51例）进行对照组研究，观察常规治疗和低分子肝素治疗的效果并进行比较。结果治疗组患者的显效率、好转率以及治疗总有效率分别为60.8%、31.4%和92.2%，均高于对照组患者的47.8%、23.9%和28.3%，差异具有统计学意义（P ＜0.05）。结论对肺心病并呼吸衰竭采用低分子肝素治疗具有疗效，能使治疗效果得到显著提高，使患者的缺氧情况、肺循环以及呼吸功能得到改善。
目的：對低分子肝素治療肺心病併呼吸衰竭的臨床效果進行研究。方法選取2013年7月～2015年7月我院接受治療的肺心病併呼吸衰竭患者97例，將患者隨機分為對照組（46例）和治療組（51例）進行對照組研究，觀察常規治療和低分子肝素治療的效果併進行比較。結果治療組患者的顯效率、好轉率以及治療總有效率分彆為60.8%、31.4%和92.2%，均高于對照組患者的47.8%、23.9%和28.3%，差異具有統計學意義（P ＜0.05）。結論對肺心病併呼吸衰竭採用低分子肝素治療具有療效，能使治療效果得到顯著提高，使患者的缺氧情況、肺循環以及呼吸功能得到改善。
목적：대저분자간소치료폐심병병호흡쇠갈적림상효과진행연구。방법선취2013년7월～2015년7월아원접수치료적폐심병병호흡쇠갈환자97례，장환자수궤분위대조조（46례）화치료조（51례）진행대조조연구，관찰상규치료화저분자간소치료적효과병진행비교。결과치료조환자적현효솔、호전솔이급치료총유효솔분별위60.8%、31.4%화92.2%，균고우대조조환자적47.8%、23.9%화28.3%，차이구유통계학의의（P ＜0.05）。결론대폐심병병호흡쇠갈채용저분자간소치료구유료효，능사치료효과득도현저제고，사환자적결양정황、폐순배이급호흡공능득도개선。
Objective To LMWH pulmonary heart disease and respiratory failure were studied clinical results. Methods In July 2013 to July 2015 in our hospital for treatment of respiratory failure in patients with pulmonary heart disease and 97 cases, the patients were randomly divided into control group (46 cases) and treatment group (51 patients) in the control group study, the observed effect of conventional treatment and low molecular weight heparin and compared. Results The treatment group were significantly efficiency improvement rate and the total effective rate was respectively 60.8%, 31.4% and 92.2%, significantly higher than 47.8% of patients, 23.9% and 28.3%, significantly different statistically significance (P<0.05). Conclusion Pulmonary Heart Disease and Respiratory Failure using low molecular weight heparin having a significant effect, the therapeutic effect can be significantly improved and the hypoxia, pulmonary circulation and respiratory function of patients improved.
